§Why CasetextPricing

National Institute on Drug Abuse; Notice of Closed Meetings

89 Fed. Reg. 78318 (Sep. 25, 2024)

National Institute on Drug Abuse; Notice of Closed Meetings

Download PDF
Federal RegisterSep 25, 2024
89 Fed. Reg. 78318 (Sep. 25, 2024)
Document Headings

Document headings vary by document type but may contain the following:

  • the agency or agencies that issued and signed a document
  • the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  • the agency docket number / agency internal file number
  • the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

    • See the Document Drafting Handbook for more details.

    Department of Health and Human Services National Institutes of Health

    Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

    The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA-K Alternate SEP.

    Date: November 4, 2024.

    Time: 3:00 p.m. to 4:00 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435-1258, marisa.srivareerat@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders.

    Date: January 8, 2025.

    Time: 10:00 a.m. to 6:30 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435-1258, marisa.srivareerat@nih.gov.

    (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

    Dated: September 20, 2024.

    Lauren A. Fleck,

    Program Analyst, Office of Federal Advisory Committee Policy.

    [FR Doc. 2024-21958 Filed 9-24-24; 8:45 am]

    BILLING CODE 4140-01-P